Background:

Galvanic current-induced vasodilation (CIV) is impaired in patients under low-dose aspirin (ASA; ≤ 500 mg/day), but potential covariates and the impact of the time since the last ASA intake are unknown.

Objectives:

We used tissue viability imaging (TiVi) in patients at risk of cardiovascular disease and examined its association with self-reported treatments.

Patients/Methods:

We recorded the age, gender, height, weight, smoking status, and use of 14 different drug categories in 822 patients either with known peripheral artery disease or at risk thereof. The difference between TiVi arbitrary units (TAUs) where stimulation was applied and an adjacent skin area was recorded, as well as the time since the last ASA intake. Step-by-step regression analysis was used to determine the factors that affect CIV amplitude.

Results and Conclusions:

CIV was 28.2 ± 22.9 vs. 14.6 ± 18.0 TAUs (p < 0.001) in patients treated with ASA (n = 287) and not treated with ASA (n = 535), respectively. The main determinants of CIV amplitude, by order of importance, were: aspirin intake, diabetes mellitus, age, and male sex. In ASA-treated patients, the main determinants were diabetes mellitus, time since the last ASA intake, male gender, and age. Non-invasive determination of the physiological effects of low-dose ASA is feasible in routine clinical practice. It could be a clinical approach to provide objective evidence of ASA intake, and potentially could be used to test adherence to treatment in ASA-treated patients.

中文翻译：

---

电流诱导的血管舒张专门检测并与最后一次阿司匹林摄入量相关：一项对 830 名患者的干预性研究

背景：

低剂量阿司匹林（ASA；≤ 500 毫克/天）患者的电流诱导血管舒张 (CIV) 受损，但潜在协变量和自最后一次 ASA 摄入以来的时间影响尚不清楚。

目标：

我们在有心血管疾病风险的患者中使用了组织活力成像 (TiVi)，并检查了其与自我报告治疗的关联。

患者/方法：

我们记录了 822 名患有已知外周动脉疾病或有患外周动脉疾病风险的患者的年龄、性别、身高、体重、吸烟状况和 14 种不同药物类别的使用情况。记录应用刺激的 TiVi 任意单位 (TAU) 与相邻皮肤区域之间的差异，以及自上次摄入 ASA 以来的时间。逐步回归分析用于确定影响 CIV 幅度的因素。

结果和结论：

接受 ASA 治疗的患者（n = 287）和未接受 ASA 治疗的患者（n = 535）的 CIV 分别为 28.2 ± 22.9 和 14.6 ± 18.0 TAU（p < 0.001）。CIV 振幅的主要决定因素，按重要性排序，是：阿司匹林摄入量、糖尿病、年龄和男性。在接受 ASA 治疗的患者中，主要决定因素是糖尿病、自上次服用 ASA 后的时间、男性和年龄。在常规临床实践中，无创测定低剂量 ASA 的生理作用是可行的。这可能是一种提供 ASA 摄入量客观证据的临床方法，并有可能用于测试 ASA 治疗患者的治疗依从性。